Melanoma Cancer Malignant melanoma of skin
Conditions
Interventions
All subjects from the two groups will undergo lymphoscintigraphy according to the protocol described below:
1. 1 mCi (37 MBq) of 99mTc-labeled nanocolloidal albumin (Nanocoll) in a volume of 0.2 ml s
Type II= TAT:60 minutes
type III= TAT: 120 minutes.
Sponsors
University of Palermo
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Study group: melanoma patients: Inclusion criteria: 1. Recent histological diagnosis of trunk or upper limbs melanoma; 2. No history or clinical findings of lymphedema, venous incompetence or trauma on the upper limbs; 3. Candidates for sentinel lymph node biopsy (SLNB); 4. Age between 18 and 75 y.o. 5. BMI between 20 and 35 kg/m2 Control group: healthy volunteers: 1. Age between 18 and 75 years 2. BMI between 20 and 35 Kg/m2 3. Males and females
Exclusion criteria
Exclusion criteria: Study group: melanoma patients: 1. Lung, brain, bones metastasis 2. History or clinical findings of lymphedema, venous incompetence or trauma on the upper limbs. 3. Previous surgery on the upper limbs 4. Allergy to the radiotracer Control group: healthy volunteers: 1. Pregnancy 2. Allergy to the radiotracer
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Upper limb lymphatic function measured through lymphoscintigraphy and using the Time of Appearance of the Tracer (TAT) to the axillary nodes at 20, 60 and 120 minutes | — |
Countries
Italy
Outcome results
None listed